Form 4: Intellia Therapeutics EVP Sells Shares Acquired Through Employee Stock Purchase Plan

Intellia Therapeutics' Executive Vice President and Chief Technical Officer, Eliana Clark, sold 1,022 shares of common stock on July 1, 2025, which were acquired through the company's Employee Stock Purchase Plan.

Summary

• Eliana Clark, Executive Vice President and Chief Technical Officer of Intellia Therapeutics, Inc. (NTLA), reported a sale of common stock.
• The transaction involved the disposition of 1,022 shares of common stock.
• The shares were sold at a price of $9.82 per share.
• The sale occurred on July 1, 2025.
• Following the transaction, Eliana Clark beneficially owns 95,369 shares of common stock.
• The shares sold were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-planned sale.

Sentiment

Score: 5

Explanation: The sale of shares by an insider is generally neutral to slightly negative. However, given that the shares were acquired through an Employee Stock Purchase Plan and the transaction was executed under a Rule 10b5-1 plan, it suggests a pre-planned liquidity event rather than a signal of lack of confidence in the company's future.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.

Risks

• Potential for negative market perception if the sale is misinterpreted as a lack of confidence in the company's future, despite being a pre-planned transaction from an Employee Stock Purchase Plan.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing for a biotechnology company. Such filings are common across all industries and do not inherently reflect broader industry trends, though the company's stock performance within the biotech sector could influence insider trading decisions.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a neutral to slightly negative signal, though the 10b5-1 plan and ESPP origin mitigate concerns.

Key Dates

Keywords

Intellia Therapeutics, NTLA, SEC Form 4, insider trading, stock sale, Eliana Clark, employee stock purchase plan, ESPP, 10b5-1 plan, biotechnology, gene editing